Terms: = Lung cancer AND BCL9, LGS, 607, ENSG00000116128, MGC131591
203 results:
1. Primary Treatment Modification and Treatment Tolerability Among Older Chemotherapy Recipients With Advanced cancer.
Mohamed MR; Rich DQ; Seplaki C; Lund JL; Flannery M; Culakova E; Magnuson A; Wells M; Tylock R; Mohile SG
JAMA Netw Open; 2024 Feb; 7(2):e2356106. PubMed ID: 38358742
[TBL] [Abstract] [Full Text] [Related]
2. Economic evaluation of serplulimab plus chemotherapy as the first-line treatment of oesophageal squamous cell carcinoma in China.
Chen F; Long Y; Yang J; Zhong K; Liu B
BMJ Open; 2023 Dec; 13(12):e078924. PubMed ID: 38149425
[TBL] [Abstract] [Full Text] [Related]
3. Risk Factors for Chronic Atrial Fibrillation Following lung Lobectomy.
Halloran SJ; Martin S; Jiang B; Bassiri A; Sinopoli J; Vargas LT; Linden PA; Towe CW
J Surg Res; 2024 Mar; 295():350-356. PubMed ID: 38064975
[TBL] [Abstract] [Full Text] [Related]
4. Assessing health-related quality of life among cancer survivors during systemic and radiation therapy in Bangladesh: a cancer-specific exploration.
Shahjalal M; Sultana M; Gow J; Hoque ME; Mistry SK; Hossain A; Mahumud RA
BMC Cancer; 2023 Dec; 23(1):1208. PubMed ID: 38062438
[TBL] [Abstract] [Full Text] [Related]
5. Multi-classification model incorporating radiomics and clinic-radiological features for predicting invasiveness and differentiation of pulmonary adenocarcinoma nodules.
Sun H; Zhang C; Ouyang A; Dai Z; Song P; Yao J
Biomed Eng Online; 2023 Nov; 22(1):112. PubMed ID: 38037082
[TBL] [Abstract] [Full Text] [Related]
6. Modulating β-catenin/bcl9 interaction with cell-membrane-camouflaged carnosic acid to inhibit Wnt pathway and enhance tumor immune response.
Gao R; Zheng X; Jiang A; He W; Liu T
Front Immunol; 2023; 14():1274223. PubMed ID: 37881428
[TBL] [Abstract] [Full Text] [Related]
7. Network Pharmacology-Based Identification of Key Pharmacological Mechanism of Shen-qi-di-huang Decoction Acting on Uremia.
Zhang X; Chen XF; Chen WJ; Ding H; Zhang BX
Altern Ther Health Med; 2024 Jan; 30(1):44-50. PubMed ID: 37773677
[TBL] [Abstract] [Full Text] [Related]
8. Immune-Related Diarrhea and Colitis in Non-small Cell lung cancers: Impact of Multidisciplinary Management in a Real-World Setting.
Bonanno L; Lorenzi M; Massa D; De Nuzzo M; Angerilli V; Zingone F; Barberio B; Russi A; Girardi F; Ferro A; Dal Maso A; Frega S; Pasello G; Dei Tos AP; Coppola M; Fassan M; Savarino EV; Guarneri V
Oncologist; 2024 Jan; 29(1):e118-e130. PubMed ID: 37603442
[TBL] [Abstract] [Full Text] [Related]
9. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Özgüroğlu M; Kilickap S; Sezer A; Gümüş M; Bondarenko I; Gogishvili M; Nechaeva M; Schenker M; Cicin I; Ho GF; Kulyaba Y; Zyuhal K; Scheusan RI; Garassino MC; He X; Kaul M; Okoye E; Li Y; Li S; Pouliot JF; Seebach F; Lowy I; Gullo G; Rietschel P
Lancet Oncol; 2023 Sep; 24(9):989-1001. PubMed ID: 37591293
[TBL] [Abstract] [Full Text] [Related]
10. Variation in Treatment Charges and Reimbursement Among Individual Thoracic Surgeons.
Mitzman B; Wang X; Haaland B; Varghese TK
Ann Thorac Surg; 2024 Mar; 117(3):645-650. PubMed ID: 37479124
[TBL] [Abstract] [Full Text] [Related]
11. Risk profiles and a concise prediction model for lymph node metastasis in patients with lung adenocarcinoma.
Liang S; Huang YY; Liu X; Wu LL; Hu Y; Ma G
J Cardiothorac Surg; 2023 Jun; 18(1):195. PubMed ID: 37340322
[TBL] [Abstract] [Full Text] [Related]
12. Measuring direct non-medical burden among patients with advanced non-small cell lung cancer in China: is there a difference in health status?
Xia Y; Chen Y; Chen J; Gan Y; Su C; Zhang H; Long E; Yan F; Yang Y
Front Public Health; 2023; 11():1090623. PubMed ID: 37213608
[TBL] [Abstract] [Full Text] [Related]
13. Association of lung Function Decline with All-Cause and cancer-Cause Mortality after World Trade Center Dust Exposure.
Goldfarb DG; Hall CB; Choi J; Zeig-Owens R; Cohen HW; Cannon M; Prezant DJ; Weiden MD
Ann Am Thorac Soc; 2023 Aug; 20(8):1136-1143. PubMed ID: 36961515
[No Abstract] [Full Text] [Related]
14. Risk of Psychiatric Disorders Among Spouses of Patients With cancer in Denmark and Sweden.
Hu K; Liu Q; László KD; Wei D; Yang F; Fall K; Adami HO; Ye W; Valdimarsdóttir UA; Li J; Fang F
JAMA Netw Open; 2023 Jan; 6(1):e2249560. PubMed ID: 36602801
[TBL] [Abstract] [Full Text] [Related]
15. Clinical features of CDK4/6 inhibitor-related interstitial lung disease in patients with breast cancer: a case series study.
Funasaka C; Naito Y; Kusuhara S; Nakao T; Nakajima H; Kawamoto M; Baba K; Mamishin K; Kondoh C; Harano K; Matsubara N; Hosono A; Sasaki T; Kawasaki T; Mukohara T
Jpn J Clin Oncol; 2023 Jan; 53(2):105-114. PubMed ID: 36373891
[TBL] [Abstract] [Full Text] [Related]
16. Segmental volumetric analysis with a ventilated or perfused area: identifying the intersegmental plane.
Kitazume M; Tane S; Shimizu N; Kitamura Y; Maniwa Y; Nishio W
Eur J Cardiothorac Surg; 2022 Nov; 62(6):. PubMed ID: 36370071
[TBL] [Abstract] [Full Text] [Related]
17. EGFR testing in paraffin-embedded cell block cytology material is reliable with increased detection for effusion fluid.
Man Ng JK; Chow C; Kin Chan RC; Pang Chan K; Xi Li JJ; Ching Li MS; To KF
Lung Cancer; 2022 Dec; 174():97-103. PubMed ID: 36356494
[TBL] [Abstract] [Full Text] [Related]
18. SNP rs9387478 at ROS1-DCBLD1 Locus is Significantly Associated with lung cancer Risk and Poor Survival in Indian Population.
Chongtham J; Pandey N; Sharma LK; Mohan A; Srivastava T
Asian Pac J Cancer Prev; 2022 Oct; 23(10):3553-3561. PubMed ID: 36308382
[TBL] [Abstract] [Full Text] [Related]
19. Genomic Landscapes and Hallmarks of Mutant RAS in Human cancers.
Scharpf RB; Balan A; Ricciuti B; Fiksel J; Cherry C; Wang C; Lenoue-Newton ML; Rizvi HA; White JR; Baras AS; Anaya J; Landon BV; Majcherska-Agrawal M; Ghanem P; Lee J; Raskin L; Park AS; Tu H; Hsu H; Arbour KC; Awad MM; Riely GJ; Lovly CM; Anagnostou V
Cancer Res; 2022 Nov; 82(21):4058-4078. PubMed ID: 36074020
[TBL] [Abstract] [Full Text] [Related]
20. The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective.
Cranmer H; Kearns I; Young M; Humphries MJ; Trueman D
J Manag Care Spec Pharm; 2022 Sep; 28(9):970-979. PubMed ID: 36001099
[No Abstract] [Full Text] [Related]
[Next]
